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Introduction. A family history of Alzheimer’s disease is a significant risk factor for its onset, but the genetic risk associated with
possessing multiple risk alleles is still poorly understood.Methods. In a sample of 95 older adults (Mean age = 75.1, 64.2% female),
we constructed a genetic risk score based on the accumulation of risk alleles in BDNF, COMT, and APOE. A neuropsychological
evaluation and consensus determined cognitive status (44 nonimpaired, 51 impaired). Logistic regression was performed to
determine whether the genetic risk score predicted cognitive impairment above and beyond that associated with each gene. Results.
An increased genetic risk score was associated with a nearly 4-fold increased risk of cognitive impairment (OR = 3.824, 𝑃 = .013)
when including the individual gene polymorphisms as covariates in the model.Discussion. A risk score combining multiple genetic
influences may be more useful in predicting late-life cognitive impairment than individual polymorphisms.
1. Introduction
A family history of late-life cognitive impairment is a well-
recognized risk factor for the development of Alzheimer’s
disease (AD) and its preclinical stage of Mild Cognitive
Impairment [1] (MCI). Twin studies report the heritability of
AD to be between 58 and 79% [2], prompting a persistent
search for genetic variants that influence susceptibility for
AD and cognitive decline. The primary genetic risk factor
for late-onset AD (LOAD) is widely considered to be the 𝜀4
allele of the apolipoprotein E (APOE) gene, which has been
consistently identified by genome-wide association studies
(GWAS) of AD [3]. In the brain, apolipoprotein E serves a
vital function in neuronal activity by regulating cholesterol
metabolism [4]. Approximately 40% of all Caucasian adults
who develop AD possess at least one 𝜀4 allele [5], and 𝜀4
carriers exhibit more precipitous cognitive decline [6, 7].
In addition to APOE, other genetic variants have been
identified as risk factors for cognitive decline because they
influence biological pathways involved in memory and exec-
utive function, which exhibit the earliest deficits during the
progression of AD [8]. For example, the BDNF gene codes
for brain-derived neurotrophic factor, a protein secreted by
neurons that promotes neurogenesis and synaptic plasticity
and transmission in the central nervous system; BDNF
is particularly critical for learning and memory processes
because it facilitates long-term potentiation in hippocampal
neurons [9]. AD has been associated with decreased BDNF
levels in the temporal and parietal cortices [10]. BDNF also
circulates and can be measured in the periphery. Decreased
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Table 1: Genotypes of BDNF, COMT, and APOE SNPs.
SNP Primer sequence Primer concentration Amplicon length Melt range (∘C)
BDNF rs6265 FW 5
󸀠-GCTTGACATCATTGGCTGAC-3󸀠 375 nM 129 70.0–92.0
RV 5󸀠-TACTGAGCATCACCCTGGAC-3󸀠
COMT rs4680 FW 5
󸀠-TCATCACCATCGAGATCAACC-3󸀠 300 nM 112 70.0–91.0
RV 5󸀠-TTTTTCCAGGTCTGACAACG-3󸀠
APOE rs429358/rs7412 FW 5
󸀠-GGCACGGCTGTCCAAGGA-3󸀠 200 nM 228 80.0–98.0
RV 5󸀠-GCCCCGGCCTGGTACAC-3󸀠
levels of serum BDNF have been associated with AD [11].
Age-related reductions in serum BDNF levels have also been
related to smaller hippocampal volume and poorer memory
function even in healthy older adults [12]. In the human
BDNF gene, variation in the protein’s function has been
attributed to a single nucleotide polymorphism (SNP, rs6265,
Val66Met) resulting in a valine (Val) to methionine (Met)
substitution at codon 66. The Met-substituted product is
associated with impaired intracellular trafficking and secre-
tion of BDNF, poorer performance in declarative memory
[13] and executive function [14], and reduced hippocampal
volume and function [13–16]. Despite these convincing links
with AD, weak association between this SNP and AD has
been identified by GWAS [17] and candidate gene studies
yield inconsistent results regarding whether the Met allele
confers an increased risk of AD [18, 19], suggesting a need
for further investigation of its role as a contributing, but not
sole, risk factor.
In addition to APOE and BDNF, the catechol-o-methyl-
transferase (COMT) gene codes for an enzyme responsible
for catalysis and inactivation of catecholamine neurotrans-
mitters such as dopamine, norepinephrine, and epinephrine
[20]. A common SNP ofCOMT (rs4680,Val158Met) involves
a substitution ofVal byMet at codon 158, the product ofwhich
is four times less metabolically active than the homozygous
Val allele product [21]. Slower enzymatic activity of COMT
delays inactivation of dopamine in the synaptic cleft in the
prefrontal cortex, resulting in enhanced executive function
for Met carriers relative to Val homozygotes [22]. Although
association between the COMT polymorphism and AD has
not been confirmed by GWAS or meta-analysis [23], studies
have demonstrated that throughout adulthood the Val allele
is associated with characteristics of cognitive decline and
dementia such as poorer performance on tasks of executive
functioning and working memory [24], declarative memory
[25], and slower processing speed [26]. As in the case of
BDNF Val66Met, the COMT Val158Met SNP is likely an
under-recognized contributing genetic risk factor in the
development of AD.
These and other genetic polymorphisms likely contribute
relatively small independent effects to collectively predispose
one to develop a complex disease such as AD. Studies have
begun to investigate how multiple genetic influences can be
aggregated into a single risk profile to predict the prevalence
or course of a given pathology, either by summing the total
number of risk alleles possessed or by obtaining a weighted
sum including each risk allele multiplied by its associated
effect size. Rodr´ıguez-Rodr´ıguez et al. [27] constructed a
genetic risk score to predict progression fromMCI toAD that
combined genotype information across 8 non-APOE genetic
variants (16 total alleles) identified by GWAS of AD risk, with
each allele weighted by its AD risk odds ratio. Although the
weighted genetic risk score was not significant, the authors
found that subjects who possessed a total of six or more
risk alleles progressed from MCI to AD twice as quickly
as those who possessed fewer than six risk alleles. While
the accumulation of risk alleles was a significant predictor
for rate of progression to AD (OR = 1.89, 𝑃 < .047, and
95% C.I. = 1.01, 3.56), each individual genetic polymorphism
did not have significant predictive power by itself, with the
exception of one marginally significant gene (CD2AP, OR =
1.69, 𝑃 < .051). Similar risk scores have been employed
to predict other pathologies such as age-related macular
degeneration, multiple sclerosis, and type II diabetes [28–
30]. These studies indicate that incorporating multiple SNPs
pertinent to a given phenotype into a genetic risk score is
more useful in predicting the prevalence or progression of a
disease than considering polymorphisms individually.
In this genetic risk score study, we took a candidate
gene approach by targeting genetic variants that have either
been identified as having a clear link with risk for AD
(i.e., APOE) or that have an important role in cognitive
and brain functions in late adulthood and have a relatively
common minor allele frequency (i.e., BDNF, COMT) but
may have been previously undetected by GWAS due to small
individual effect sizes. To test whether the combination of
these three risk genotypes was collectively predictive of late-
life cognitive impairment, we created a cumulative genetic
risk score by summing the possession or absence of each
SNP’s risk allele. We predicted that a higher genetic risk
score would correspond to an increased risk of cognitive
impairment above and beyond that of the individual gene
polymorphisms.
2. Methods
2.1. Participants. Data for this study were collected as part
of a larger study examining the utility of providing cognitive
testing of older adults in primary care physician (PCP) offices
[31, 32]. Participants included 109 adults who were consented
into the parent study. The parent study recruited participants
from eleven PCP practices in the greater Pittsburgh and
surrounding areas. Participants were eligible to participate if
they were 65 years or older, had no medical chart diagnosis
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of dementia, had no acute illness, and were not residing
in a nursing home. They were excluded if initial screening
revealed the presence of sensory deficits that would pre-
clude computerized and paper and pencil neuropsychological
testing. Additionally, they were excluded if initial screening
revealed the presence of dementia as indicated by a score of
≤18 on the Mini-Mental State Examination [33].
One participant was removed due to incorrectly recorded
cognitive data. Since distributions of allelic frequencies dif-
fer between races, 4 African American participants were
removed from the analysis to minimize confounding by
genetic admixture. Age, gender, and years of education
were self-reported. All participants signed a consent form
approved by theUniversity of Pittsburgh Institutional Review
Board and were remunerated $20 for participation.
2.2. Cognitive Assessment and Group Classification. Each
participant completed a comprehensive neuropsychologi-
cal test battery assessing five primary cognitive domains:
memory, executive function, spatial ability, language, and
attention/psychomotor speed. Measures of memory were the
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) Word List Learning Test with delayed recall [34],
the Wechsler Memory Scale-Revised Logical Memory I and
II [35], and themodified Rey-Osterrieth figure for immediate
and delayed recall [36]. Tests of executive function were the
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Back-
ward Digit Span [37], the controlled oral word association
test (FAS) [38], Part B of the Trail-Making Test [39], the
WAIS-R Digit Symbol [37], and the Clock Drawing Test [38].
Tests of spatial ability were themodified Rey-Osterrieth Copy
[36] and the modified WAIS-R Block Design [37]. Language
tests consisted of the Boston Naming Test [40] and semantic
fluency (animals) [38]. Tests of attention/psychomotor speed
were the WAIS-R Digit Span Forward [37] and Part A of the
Trail-Making Test [39]. Participants were also administered
the Center for Epidemiologic Studies Depression (CES-
D) Scale[41] for assessment of depression symptomatology,
the Activities of Daily Living (ADL) Scale [42], and the
Instrumental Activities of Daily Living (IADL) Scale [43].
A clinical adjudication panel of three expert neuropsy-
chologists (all licensed psychologists) determined cognitive
status: normal, mild cognitive impairment (MCI), or demen-
tia. Classifications were done according to the criteria from
the University of Pittsburgh Alzheimer’s Disease Research
Center [44, 45]. Dementia range = scores ≥ 2SD below age
norms on two cognitive domains, one ofwhichmust bemem-
ory; MCI range = at least two scores 1-2SD below age norms;
normal cognition = individuals not included in ranges for
either dementia orMCI.Thefinal diagnosis took into account
the cognitive test scores as well as demographic, functional,
behavioral, and medical information. Adjudications were
conducted blind to study group status of the parent study.
Final cognitive status categories consisted of cognitively
nonimpaired (𝑛 = 44), Mild Cognitive Impairment (MCI,
𝑛 = 47), or dementia (𝑛 = 4). Because of the low number of
individuals with dementia, those with either Mild Cognitive
Impairment or dementia were combined into a single group
labeled “cognitive impairment” (𝑛 = 51).
2.3. Genotype Collection, Coding, and Risk Score Computa-
tion. Genomic DNA was collected with the Oragene-DNA
Self-Collection Kit OG-500 (DNA Genotek Inc., Ontario,
Canada). Extraction andpurification ofDNAwere completed
using the laboratory protocol fromOragene-DNA. DNA was
diluted with TE buffer to 10 ng/𝜇L and stored at −20∘C.
Participants were genotyped for rs6265 (Val66Met) in
BDNF, rs4680 (Val158Met) in COMT, and rs429358/rs7412
in APOE (ApoE2, ApoE3, and ApoE4). Genotype analysis
was performed by high-resolution melting (HRM) analysis.
Each polymerase chain reaction (PCR) was performed on a
CFX96 real-time PCR system (Bio-Rad, Hercules, CA) using
1x Precision Melt Supermix (Bio-Rad, Hercules, CA). The
reaction volume was 20 𝜇L and contained 50 ng of genomic
DNA. See Table 1 for primer sequence, primer concentration,
amplicon length, and melt range. The running conditions
for BDNF were 1 cycle of 95∘C for 2min and 65 cycles of
95∘C for 10 s, and 56.6∘C for 30 sec. The running conditions
for COMT were 1 cycle of 95∘C for 2min and 65 cycles
of 95∘C for 10 s, and 60.1∘C for 30 sec. The conditions for
APOE were 1 cycle of 95∘C for 2min and 60 cycles of 95∘C
for 10 s, 63.8∘C for 30 s, and 72∘C for 30 sec. The melting
range varied per SNP (see Table 1) but all began with a
heteroduplex formation of 95∘C for 30 seconds and 60∘C for
1min. The temperature increment for melting analysis for all
three genotypes was 0.2∘C per 10 sec. The melting curve was
analyzed using Bio-Rad Precision Melt Analysis 1.2 software.
Negative and positive controls were included on each run
to ensure genotyping accuracy. Greater than 50% of samples
were run in duplicate.
For the individual genotype analyses, BDNF genotype
groups consisted of Val homozygotes, Val heterozygotes,
and Met homozygotes; COMT genotype groups similarly
consisted of Val homozygotes, Val heterozygotes, or Met
homozygotes; APOE genotype groups included 𝜀2/𝜀3, 𝜀2/𝜀4,
𝜀3/𝜀3, 𝜀3/𝜀4, or 𝜀4/𝜀4. See Table 2 for genotype frequencies.
The genetic risk score was then computed for each
participant by summing the presence or the absence of risk
genotypes. That is, each genotype was assigned either “0”
for minimally associated genetic risk with cognitive deficits
or “1” for a putative association with cognitive deficits. This
scoring criterion was based on the literature for each of
the three polymorphisms. For APOE, the 𝜀4 allele is widely
considered to be a risk allele for cognitive deficits and decline;
so its possession warranted “1” towards the risk score and
its absence “0”. For BDNF, the Met allele is associated with
decreased cognitive function; so possession of a Met allele
resulted in “1” and its absence “0”. For COMT, the Val allele
is considered to be most strongly associated with cognitive
deficits, conferring “1” for its possession and “0” in its
absence.
In effect, the risk score combines BDNFMet carriers into
one group to be compared with Val homozygotes due to our
interest in possession of the Met allele at either locus. In a
similar fashion, homozygous and heterozygous COMT Val
carriers were grouped and compared withMet homozygotes.
Following convention established by the APOE literature, 𝜀4
allele carriers were grouped and compared with all non-𝜀4
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Table 2: Frequencies of BDNF, COMT, and APOE genotypes and
risk allele carriers.
Gene Genotype 𝑛 Risk allele carrier status 𝑛
BDNF
Val/Val 61 Met carriers (risk score value = 1) 34
Val/Met 33 Val homozygotes (risk score value = 0) 61
Met/Met 1
COMT
Val/Val 23 Val carriers (risk score value = 1) 63
Val/Met 40 Met homozygotes (risk score value = 0) 32
Met/Met 32
APOE
𝜀2/𝜀3 12 𝜀4 carriers (risk score value = 1) 22
𝜀2/𝜀4 1 Non-𝜀4 carriers (risk score value = 0) 73
𝜀3/𝜀3 61
𝜀3/𝜀4 18
𝜀4/𝜀4 3
carriers. See Table 2 for risk genotype frequencies for each
gene.
The sum of these three component risk genotypes for
all three polymorphisms yielded a risk score with a scale of
genetic risk values between 0 and 3. An overall risk score
value of “0” translates into the absence of any risk genotypes
and represents the lowest genetic risk category for decline in
cognitive status; “1” represents possession of only one risk
genotype, “2” represents possession of two risk genotypes,
and “3” represents possession of all 3 risk genotypes and is
proposed to represent the highest genetic risk category for
decline in cognitive status.
2.4. Statistics. First, in order to determine whether any of
the three genotypes were individually predictive of cognitive
status, hierarchal logistic regression analyses were performed
(SPSS Version 22). The demographic variables, consisting of
age, gender, and years of education, comprised the 1st block
while BDNF, COMT, and APOE genotype were each entered
as the 2nd block in separate regression models. In these
analyses, the BDNF genotype was coded as “1” for Val/Val,
“2” for Val/Met, or “3” for Met/Met. In a similar fashion, the
COMT genotypewas coded as “1” forVal/Val, “2” forVal/Met,
or “3” for Met/Met. Based on the literature, the independent
effect of APOE genotype on cognitive status was determined
by assigning “1” for non-𝜀4 carriers and “2” for the possession
of at least one 𝜀4 allele; for subsequent risk score analyses,
the APOE genotype variable reflects all possible genotypes,
coded as “23” for 𝜀2/𝜀3, “24” for 𝜀2/𝜀4, “33” for 𝜀3/𝜀3, “34”
for 𝜀3/𝜀4, and “44” for 𝜀4/𝜀4. These genotype variables were
subsequently used as the individual genotype covariates in
the genetic risk score analyses.
Hierarchal logistic regression was then performed to
determine whether the composite genetic risk score variable
(entered as the 3rd block) predicted cognitive status (non-
impaired versus impaired) above and beyond the individual
genotypes (all three comprising the 2nd block) and the
demographic variables (the 1st block). We report odds ratios
(OR) and confidence intervals (C.I.) resulting from these
analyses and report 𝑃 values below 0.05.
Table 3: Participant demographics.
Characteristic
All partici-
pants
(n = 95)
Nonimpaired
(n = 44)
Impaired
(n = 51)
Age (mean years
[SD]) 75.1 (5) 73.9 (4.2) 76.1 (5.4)
Completed
education
(mean years
[SD])
14.4 (3.2) 15.1 (2.9) 13.8 (3.3)
Gender (%
female) 64.2 70.5 58.8
MMSE (mean
[SD]) 28.1 (2.1) 28.9 (1.2) 27.5 (2.4)
3. Results
3.1. Demographics and Covariates. Nine participants were
excluded (7 were missing genotype information for all three
genes while an additional 2 were missing APOE genotype,
resulting in an overall failure rate of 7.37% and error rate
of 0%). Our final sample size of 𝑛 = 95 was 64.2% female
with a mean age of 75.1 years. Allelic frequencies did not
significantly differ fromHardy-Weinberg equilibrium for any
of the three genes. Table 3 shows demographic information
and MMSE scores for the overall sample as well as between
the nonimpaired and impaired participants. Cognitive status
(the presence or absence of impairment) was significantly
associated with age (OR = 1.113, 𝑃 = .025, and 95% C.I. =
1.014, 1.222) and years of education (OR = .861, 𝑃 = .038, and
95% C.I. = .748, .992) such that higher age and fewer years of
education were associated with a higher risk of impairment.
Gender was not significantly associated with an increased
risk of impairment (OR = .537, 𝑃 = .177, and 95% C.I. =
.217, 1.324), but there were a higher proportion of men in the
cognitively impaired group and there is evidence of sexual
dimorphismof bothBDNF andAPOE on risk forAD [46, 47].
Therefore, we included age, gender, and years of education
as covariates in all analyses to isolate the effects of BDNF,
COMT, and APOE genotype or the genetic risk score on
cognitive status. See Table 3.
3.2. Association between Individual SNPs and Risk for Cog-
nitive Impairment. Consistent with the literature, APOE 𝜀4
carrier status was significantly predictive of an increased risk
of cognitive impairment (OR=3.561,𝑃 = .032, and 95%C.I. =
1.116, 11.365) after controlling variation from age, gender, and
education. Neither BDNF norCOMT genotype was related to
cognitive status (BDNF, OR = 1.149, 𝑃 = .755, and 95% C.I. =
.479, 2.759;COMT, OR = 1.074,𝑃 = .808, and 95%C.I. = .606,
1.903).
3.3. Association between Genetic Risk Score and Risk for
Cognitive Impairment. Table 4 shows the frequencies for each
genetic risk score value. Each additional point towards the
genetic risk score was significantly associated with a nearly
4-fold increased risk of cognitive impairment (OR = 3.824,
Journal of Aging Research 5
Table 4: Genetic risk score frequencies.
Risk score value 𝑛
0 16
1 46
2 26
3 7
Total 95
Table 5: Results of genetic risk score controlling individual geno-
types.
Variable OR 𝑝 value 95% C.I.
BDNF 0.369 0.145 0.096–1.410
COMT 2.147 0.061 0.966–4.773
APOE 0.9 0.093 0.796–1.018
Risk score 3.824 0.013 1.333–10.973
𝑃 = .013, and 95% C.I. = 1.333, 10.973) even after including
all of the individual gene polymorphisms in the model (see
Table 5). Consistent with our hypothesis, a higher genetic risk
score representing an increasing number of risk genotypes
was predictive of an increased risk of cognitive impairment
above and beyond the variation attributable to individual
polymorphisms. Figure 1 shows the distribution of risk scores
between cognitive status categories.
Follow-up analyses were performed to determine
whether the 4 individuals with dementia were driving the
association between the genetic risk score and cognitive
impairment. After removing the 4 individuals with dementia
from the analysis, the risk score remained significant (OR =
3.138, 𝑃 = .039, and 95% C.I. = 1.059, 9.302) while the
individual genotypes remained nonsignificant in the full
model, with the exception of COMT which reached nominal
significance (BDNF, OR = .446, 𝑃 = .248, and 95% C.I. =
.113, 1.755; COMT, OR = 1.977, 𝑃 = .095, and 95% C.I. = .889,
4.396; APOE, OR = .899, 𝑃 = .105, and 95% C.I. = .790,
1.022).
4. Discussion
We created a genetic risk score to represent the accumulation
of risk genotypes of polymorphisms in BDNF, COMT, and
APOE to test whether the risk score predicted the presence
of late-life cognitive impairment above and beyond that of
each individual gene polymorphism. Consistent with our
predictions, a higher genetic risk score significantly predicted
a higher risk of having cognitive impairment (OR= 3.824,𝑃 =
.013, and 95%C.I. = 1.333, 10.973)when controlling individual
polymorphisms in BDNF, COMT, and APOE (see Tables 4
and 5). Congruent with the literature, BDNF and COMT
genotype were not independently predictive of cognitive
status, whereas APOE 𝜀4 carrier status was predictive of
cognitive status (OR = 3.561, 𝑃 = .032, and 95% C.I. =
1.116, 11.365). These results demonstrate that the aggregation
of multiple risk genotypes into one total risk score predicted
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Figure 1: Risk score frequencies between cognitive status categories.
the presence or absence of impairment to a higher degree
than any of the individual polymorphisms.
The genes under consideration for this study were chosen
due to their involvement in general neural function (APOE)
as well as in processes known to present the earliest deficits in
AD such as learning,memory, and executive function (BDNF
and COMT). Polymorphisms in these genes (BDNF, rs6265;
COMT, rs4680; and APOE, rs429358/rs7412) have been
associated with differential protein function, with possession
of each SNP’s risk allele (Met, Val, and 𝜀4, resp.) associated
with poorer cognitive performance. Our findings support the
use of a single genetic risk score to represent the accumulation
of genetic influences affecting multiple domains of cognition
and brain health in relation toAD,whichmay bemore impor-
tant in determining cognitive decline than testing individual
genotypes.When considered individually, these same genetic
polymorphisms contribute small or negligible effects and
remain largely undetected by previous GWAs (except APOE)
but may still represent influential aspects of AD pathology.
These results beg the question of the importance of other
risk genotypes not assessed here that could also contribute
to risk of AD. Additionally, our results complement previous
reports of significant interaction between COMT Val158Met
and APOE 𝜀4 on risk for AD [48], additive effects of BDNF
Val66Met and APOE 𝜀4 on hippocampal activity in healthy
older adults [49], and interaction between BDNF Val66Met
and APOE 𝜀4 on episodic memory in cognitively healthy
older adults [50].
Our study represented a unique population of older
adults who underwent a comprehensive cognitive assessment
and diagnosis. However, one limitation is the relatively
small sample size of our study (𝑛 = 95). In genetic
association studies, hundreds of subjects are genotyped in
order to achieve sufficient power to reliably test specific
genetic interactions or confirm epistatic effects between
genes. However, we still detected an association between
higher risk scores and increased odds of being cognitively
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impaired (Figure 1). Future studies will need to expand
these results to larger samples with a higher proportion of
cognitively impaired individuals. This will help verify the
associations to more clearly examine potential interactions
between these gene polymorphisms as well as assess effect
sizes and dose-dependent effects of possessing one, both, or
no risk allele(s) for each gene considered. The genetic risk
score reported here was unable to account for and examine
the effects of possessing either one or both risk alleles for each
gene without further reducing the number of participants
in each risk score category and diminishing the statistical
power and interpretation of the results. Finally, an additional
limitation of the current study is that we included only
individuals of European descent to avoid confounding by
population admixture. Future studies should recruit from
various racial and ethnic backgrounds to determine whether
the genetic and phenotypic trends observed here are present
in other races and ethnicities while adequately accounting for
population stratification.
In summary, we found that a cumulative genetic risk score
across three genes related to cognition, brain function, and
risk for dementia (BDNF, COMT, and APOE) significantly
predicted late-life cognitive impairment. The risk score was
significant above and beyond the effects of each individual
genotype. Our findings demonstrate the effectiveness of
genetic risk scores and their potential utility as predictors
of more genetic variation in cognitive outcomes such as AD
than polymorphisms considered individually.
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